The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I'm interested in knowing what JKs game plan is. Not likely to be a takeover and he must be underwater at the moment. Perhaps just an investment for the benefit of Mr Kight (sorry Beatles I couldn't resist that one)
No it's not AGM.
Isn't that an annual General meeting, I seem to recall they didn't take any questions the last time.
I'm thinking Kight is done with his buying, got to around the maximum permissible amount (£2 million) he can use within his tax scheme.
Now over to the directors to step in.
I hear they are considering doing a webinar where investors can ask questions of Huw/the directors in the next few months.
If/when this happens I assume you will be there Kingalf?
These interviews are so scripted, the 2 questions she should have asked were, if you feel so confident, why haven't you invested directly yourself and secondly, any views on this new investor who has built a 11% plus holding in your company.
Cheers Troajan, lots going on this year and plenty of newsflow over the coming months. Might actually see the SP start to rise at some point!
"Ramping up staff has produced huge benefits"
I take it that he means staff pockets, it certainly hasn't benefited the shareholders.
It's like a season finali of a never ending series, gives you enough to come back and watch the next series, but we all secretly know it will be same old story line going forward.
If the share price keeps dropping, it will be more cost effective for Juvenescence to buyout the company then pay any future royalties.
Brexit helps speed up delivery of new cancer drugs to UK patients
http://digitaleditions.telegraph.co.uk/data/856/reader/reader.html?social#!preferred/0/package/856/pub/856/page/110/article/264948
As well as the significant “nutritional health product” opportunity with Juvenscence that I have flagged up previously, that will not require the burden of undertaking medical trials/approvals. Noteworthy that EVG already received 0.25 MUSD initial payment when that agreement was signed which is a strong sign of their serious intentions for achieving the product launch (targeted for launch within this year as per related RNS guidance).
"As such, they could constitute follow-on and/or alternative products which would expand Evgen's development and partnering opportunities."
Could.....not will. Nonetheless it is good to be invested in a company with a pipeline of potential drugs rather than just one potential blockbuster etc.
great news.
RNS Number : 7343Y
Evgen Pharma PLC
18 January 2022
Evgen Pharma plc
("Evgen" or "the Company")
Option over new sulforaphane analogues
Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane-based medicines for the treatment of multiple diseases, announces a Memorandum of Understanding with the University of Seville ('US'), Consejo Superior de Investigaciones Científicas ('CSIC') and Fundación Pública Andaluza Progreso y Salud on behalf of the Institute of Biomedicine of Seville, for second generation sulforaphane analogues.
Under the agreement Evgen has signed an exclusive option to license new, novel sulforaphane analogues synthesised by these Spanish institutions, subject to a fixed evaluation period. These analogues have the potential for differentiation from SFX-01 in terms of product formulation. They may also have the potential for differential activity against targets that Evgen is pursuing such as STAT3, SHP2 and Nrf2. As such, they could constitute follow-on and/or alternative products which would expand Evgen's development and partnering opportunities.
If the option is exercised it would expand substantially Evgen's preclinical pipeline of sulforaphane analogues. Analogues from an existing license from US and CSIC are currently undergoing further screening against relevant targets. The current option will be exercised should the Company's technical evaluation be positive.
Dr Huw Jones, Chief Executive Officer of Evgen Pharma, said: "I am delighted that we are extending our collaboration with the CSIC and University of Seville, and the opportunity this gives us to broaden our sulforaphane-based drug pipeline. If differentiation is demonstrated in the laboratory, we then have considerable potential to target diseases where one of the key molecular targets for sulforaphane is more relevant than others, enhancing our pipeline substantially."
As soon as it dipped below 5p today it looks like Kight was at it again sweeping up roughly another 1/2 million shares in chunks and the ask price quickly returned back to 5.2p …..TR-1 envisaged shortly.
You do post some sh*t Kingalf.
Seems to have hit a support line stretching back to March 2020. Clearly the seller wasn't happy that they've blown a load of cash revamping their website.
My conspiracy theory……..
The question I keep asking myself is why a guy who is a long term director/manager in the unrelated Computer business (Google search of his name gives you this insight) who has no apparent connection to the medical sector is amassing such a significant % stake in EVG ???
The only “coincidence” that I have noted from Google search is that the registered office addresses of EVG and Kight’s Computer business are closeby in same geographic UK locality of Altrincham (near Manchester/Liverpool).
So perhaps there could be a connection whereby Kight moves in the same social circles as EVG Mgt rep(s) and has close knowledge towards the EVG business being gleaned from such relations ???
This is pure conjecture on my part, but to me there seems to be more to Kight’s significant investment in EVG than meets the eye here and so I for one believe it’s worth riding on his coat-tail and having a small investment in EVG to see how this plays out.
DYOR
I think EIS would only be possible in a placing of new shares, whereas Kight has clearly bought in the open market.
Not sure if he has already reached it, but I suspect he will be investing a total of £2 million.
Evgen does fall under a knowledge-intensive company.
EIS Investments
When you invest in young, small companies that qualify for the Enterprise Investment Scheme (EIS) you could generate significant returns if the company prospers.
But that’s far from certain. Investing in this kind of business is risky and many will fail. Therefore, to encourage investment and to temper some of the risk, the government offers generous EIS tax reliefs:
Save up to 30% on your income tax bill – up to £300,000 per year (or £600,000 when investing in knowledge-intensive companies)
Very generous allowance – up to £1 million (or £2 million if anything above £1 million is invested in knowledge-intensive companies)
Enjoy tax-free growth
Defer capital gains from other investments – potentially indefinitely
Offset any future losses against your income, so you save income tax
Pass on your investment free of IHT
It’s important to bear in mind the non pharmaceutical application ((nutritional health product) License Agreement that has been established with Juvenscence, which potentially gives EVG a significant revenue stream to kick in later this year. This opportunity positively differentiates them from most other typical clinical stage pharma small caps.
https://www.lse.co.uk/rns/EVG/licence-agreement-with-juvenescence-4eyt1kohym361fs.html
Bonkers market cap here - they should really look into a US listing, especially if the glioma trial is going to be partly US-based.
Let's not lose sight of the fact that this stock has a £14m market cap with £10m net cash!
Then some great news in todays announcement (and previous ones) easyp - this drug will be in clinical trials this year - hopefully by Q2!
"I am delighted with the positive progress that has been made with MHRA and FDA regarding our two planned clinical trials for SFX-01, both of which we intend to commence later this year."
I know from bitter experience with bio-techs that while the sp can be traded for profit along the road until a company has a drug in the phase 1/2/3 trials then the sp unlikely to take off. Hence I will have to wait a year or two to see a return on my punt.